IDEAS home Printed from https://ideas.repec.org/f/pca989.html
   My authors  Follow this author

Colleen Marie Carey

Personal Details

First Name:Colleen
Middle Name:Marie
Last Name:Carey
Suffix:
RePEc Short-ID:pca989
[This author has chosen not to make the email address public]
https://sites.google.com/site/colleenmariecarey

Affiliation

Jeb E. Brooks School of Public Policy
Cornell University

Ithaca, New York (United States)
https://publicpolicy.cornell.edu/
RePEc:edi:dpcorus (more details at EDIRC)

Research output

as
Jump to: Working papers Articles

Working papers

  1. Thomas C. Buchmueller & Colleen Carey, 2017. "The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare," NBER Working Papers 23148, National Bureau of Economic Research, Inc.

Articles

  1. Thomas C. Buchmueller & Colleen Carey, 2018. "The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare," American Economic Journal: Economic Policy, American Economic Association, vol. 10(1), pages 77-112, February.
  2. Colleen Carey, 2017. "Technological Change and Risk Adjustment: Benefit Design Incentives in Medicare Part D," American Economic Journal: Economic Policy, American Economic Association, vol. 9(1), pages 38-73, February.
  3. Colleen Carey & Stephen H. Shore, 2013. "From the Peaks to the Valleys: Cross-State Evidence on Income Volatility over the Business Cycle," The Review of Economics and Statistics, MIT Press, vol. 95(2), pages 549-562, May.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Thomas C. Buchmueller & Colleen Carey, 2017. "The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare," NBER Working Papers 23148, National Bureau of Economic Research, Inc.

    Cited by:

    1. Ruenzi, Stefan & Maeckle, Kai, 2023. "Friends with Drugs: The Role of Social Networks in the Opioid Epidemic," VfS Annual Conference 2023 (Regensburg): Growth and the "sociale Frage" 277574, Verein für Socialpolitik / German Economic Association.
    2. David Cho & Daniel I. García & Joshua Montes & Alison E. Weingarden, 2021. "Labor Market Effects of the Oxycodone-Heroin Epidemic," Finance and Economics Discussion Series 2021-025, Board of Governors of the Federal Reserve System (U.S.).
    3. Christopher J. Ruhm, 2018. "Deaths of Despair or Drug Problems?," NBER Working Papers 24188, National Bureau of Economic Research, Inc.
    4. Molly Schnell & Janet Currie, 2017. "Addressing the Opioid Epidemic: Is There a Role for Physician Education?," NBER Working Papers 23645, National Bureau of Economic Research, Inc.
    5. Diwas KC & TI Tongil Kim & Jiayi Liu, 2022. "Electronic prescription monitoring and the opioid epidemic," Production and Operations Management, Production and Operations Management Society, vol. 31(11), pages 4057-4074, November.
    6. Dow, Wiiliam H & Godoey, Anna & Lowenstein, Christopher A & Reich, Michael, 2019. "Can Economic Policies Reduce Deaths of Despair? Working Paper #104-19," Institute for Research on Labor and Employment, Working Paper Series qt14f015df, Institute of Industrial Relations, UC Berkeley.
    7. Beth Ann Griffin & Megan S. Schuler & Elizabeth A. Stuart & Stephen Patrick & Elizabeth McNeer & Rosanna Smart & David Powell & Bradley Stein & Terry Schell & Rosalie Liccardo Pacula, 2020. "Variation in Performance of Commonly Used Statistical Methods for Estimating Effectiveness of State-Level Opioid Policies on Opioid-Related Mortality," NBER Working Papers 27029, National Bureau of Economic Research, Inc.
    8. Ahammer, Alexander & Packham, Analisa, 2024. "Supply-Side Drug Policy, Polydrug Use, and the Economic Effects of Withdrawal Symptoms," IZA Discussion Papers 17192, Institute of Labor Economics (IZA).
    9. Pohl, R. Vincent, 2018. "Time Trends Matter: The Case of Medical Cannabis Laws and Opioid Overdose Mortality," MPRA Paper 88219, University Library of Munich, Germany.
    10. Christopher J. Ruhm, 2019. "Shackling the Identification Police?," Southern Economic Journal, John Wiley & Sons, vol. 85(4), pages 1016-1026, April.
    11. Borgschulte, Mark & Corredor-Waldron, Adriana & Marshall, Guillermo, 2018. "A Path Out: Prescription Drug Abuse, Treatment, and Suicide," IZA Discussion Papers 11391, Institute of Labor Economics (IZA).
    12. Alexander Ahammer, 2019. "A novel supply-side measure to combat abuse of addictive prescription drugs," Economics working papers 2019-11, Department of Economics, Johannes Kepler University Linz, Austria.
    13. Gihleb, Rania & Giuntella, Osea & Zhang, Ning, 2018. "The Effects of Mandatory Prescription Drug Monitoring Programs on Foster Care Admissions," IZA Discussion Papers 11470, Institute of Labor Economics (IZA).
    14. Dhaval Dave & Monica Deza & Brady Horn, 2021. "Prescription drug monitoring programs, opioid abuse, and crime," Southern Economic Journal, John Wiley & Sons, vol. 87(3), pages 808-848, January.
    15. Mayank Aggarwal & Anindya S. Chakrabarti & Chirantan Chatterjee, 2023. "Movies, stigma and choice: Evidence from the pharmaceutical industry," Health Economics, John Wiley & Sons, Ltd., vol. 32(5), pages 1019-1039, May.
    16. Orgul Ozturk & Yuan Hong & Suzanne McDermott & Margaret Turk, 2021. "Prescription Drug Monitoring Programs and Opioid Prescriptions for Disability Conditions," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 415-428, May.
    17. Engy Ziedan & Robert Kaestner, 2020. "Effect of Prescription Opioids and Prescription Opioid Control Policies on Infant Health," NBER Working Papers 26749, National Bureau of Economic Research, Inc.
    18. Harris, Matthew & Kessler, Lawrence & Murray, Matthew & Glenn, Beth, 2017. "Prescription Opioids and Labor Market Pains: The Effect of Schedule II Opioids on Labor Force Participation and Unemployment," MPRA Paper 86586, University Library of Munich, Germany, revised 28 Mar 2018.
    19. Janet Currie & Hannes Schwandt, 2021. "The Opioid Epidemic Was Not Caused by Economic Distress but by Factors That Could Be More Rapidly Addressed," The ANNALS of the American Academy of Political and Social Science, , vol. 695(1), pages 276-291, May.
    20. Simone Balestra & Helge Liebert & Nicole Maestas & Tisamarie B. Sherry, 2022. "Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic," CESifo Working Paper Series 9704, CESifo.
    21. Aliprantis, Dionissi & Fee, Kyle & Schweitzer, Mark E., 2023. "Opioids and the labor market," Labour Economics, Elsevier, vol. 85(C).
    22. Abouk, Rahi & Powell, David, 2021. "Can electronic prescribing mandates reduce opioid-related overdoses?," Economics & Human Biology, Elsevier, vol. 42(C).
    23. Alexander Ahammer & Martin Halla, 2022. "The intergenerational persistence of opioid dependence: Evidence from administrative data," Health Economics, John Wiley & Sons, Ltd., vol. 31(11), pages 2425-2444, November.
    24. Ahammer, Alexander & Halla, Martin, 2020. "The Intergenerational Transmission of Opioid Dependence: Evidence from Administrative Data," IZA Discussion Papers 13395, Institute of Labor Economics (IZA).
    25. Alberto Ortega, 2023. "Medicaid Expansion and mental health treatment: Evidence from the Affordable Care Act," Health Economics, John Wiley & Sons, Ltd., vol. 32(4), pages 755-806, April.
    26. Keith Marzilli Ericson & Adam Sacarny & R. Annetta Zhou, 2022. "Dangerous Prescribing and Healthcare Fragmentation: Evidence from Opioids," NBER Working Papers 29992, National Bureau of Economic Research, Inc.
    27. Packham, Analisa, 2022. "Syringe exchange programs and harm reduction: New evidence in the wake of the opioid epidemic," Journal of Public Economics, Elsevier, vol. 215(C).
    28. Natali, Ilaria, 2024. "Economic Opportunity and Opioid Regulation: the Case of Codeine in France," TSE Working Papers 24-1563, Toulouse School of Economics (TSE).
    29. Amy Finkelstein & Matthew Gentzkow & Dean Li & Heidi L. Williams, 2022. "What Drives Risky Prescription Opioid Use? Evidence from Migration," NBER Working Papers 30471, National Bureau of Economic Research, Inc.
    30. Hollingsworth, Alex & Ruhm, Christopher J. & Simon, Kosali, 2017. "Macroeconomic conditions and opioid abuse," Journal of Health Economics, Elsevier, vol. 56(C), pages 222-233.
    31. Aparna Soni, 2024. "Estimating price elasticities of demand for pain relief drugs: evidence from Medicare Part D," International Journal of Health Economics and Management, Springer, vol. 24(4), pages 481-515, December.
    32. Lindsey Rose Bullinger & Benjamin C. Ward, 2021. "What about the children? How opioid use affects child well‐being," Contemporary Economic Policy, Western Economic Association International, vol. 39(4), pages 737-759, October.
    33. Eli B. Liebman & Emily C. Lawler & Abe Dunn & David B. Ridley, 2023. "Consequences of a Shortage and Rationing: Evidence from a Pediatric Vaccine," NBER Working Papers 31479, National Bureau of Economic Research, Inc.
    34. Gihleb, Rania & Giuntella, Osea & Zhang, Ning, 2019. "Prescription Drug Monitoring Programs and Neonatal Outcomes," IZA Discussion Papers 12796, Institute of Labor Economics (IZA).
    35. Kaestner, Robert & Ziedan, Engy, 2023. "Effects of prescription opioids on employment, earnings, marriage, disability and mortality: Evidence from state opioid control policies," Labour Economics, Elsevier, vol. 82(C).
    36. Chatterji, Pinka & Nguyen, Trang & Ncube, Butho & Dennison, Barbara A., 2022. "Effects of New York state paid family leave on early immunizations," Social Science & Medicine, Elsevier, vol. 315(C).
    37. Janet Currie & Hannes Schwandt, 2020. "The Opioid Epidemic Was Not Primarily Caused by Economic Distress But by Other Factors that Can be More Readily Addressed," Working Papers 2020-25, Princeton University. Economics Department..
    38. Analisa Packham, 2019. "Are Syringe Exchange Programs Helpful or Harmful? New Evidence in the Wake of the Opioid Epidemic," NBER Working Papers 26111, National Bureau of Economic Research, Inc.
    39. David Cho & Alvaro Mezza & Joshua Montes, 2022. "Choices and Implications when Measuring the Local Supply of Prescription Opioids," Finance and Economics Discussion Series 2022-078, Board of Governors of the Federal Reserve System (U.S.).
    40. Daniel W. Sacks & Alex Hollingsworth & Thuy D. Nguyen & Kosali I. Simon, 2019. "Can Policy Affect Initiation of Addictive Substance Use? Evidence from Opioid Prescribing," NBER Working Papers 25974, National Bureau of Economic Research, Inc.
    41. Janssen, Aljoscha & Zhang, Xuan, 2020. "Retail Pharmacies and Drug Diversion during the Opioid Epidemic," Working Paper Series 1373, Research Institute of Industrial Economics.
    42. Aljoscha Janssen & Xuan Zhang, 2023. "Retail Pharmacies and Drug Diversion during the Opioid Epidemic," American Economic Review, American Economic Association, vol. 113(1), pages 1-33, January.
    43. Cotti, Chad D. & Gordanier, John M. & Ozturk, Orgul D., 2020. "The relationship of opioid prescriptions and the educational performance of children," Social Science & Medicine, Elsevier, vol. 265(C).
    44. Thuy D. Nguyen & W. David Bradford & Kosali I. Simon, 2019. "How do Opioid Prescribing Restrictions Affect Pharmaceutical Promotion? Lessons from the Mandatory Access Prescription Drug Monitoring Programs," NBER Working Papers 26356, National Bureau of Economic Research, Inc.
    45. Thomas C. Buchmueller & Colleen M. Carey & Giacomo Meille, 2019. "How Well Do Doctors Know Their Patients? Evidence from a Mandatory Access Prescription Drug Monitoring Program," NBER Working Papers 26159, National Bureau of Economic Research, Inc.
    46. Claudio Deiana & Ludovica Giua & Roberto Nisticò, 2024. "Opium Price Shocks and Prescription Opioids in the USA," Oxford Bulletin of Economics and Statistics, Department of Economics, University of Oxford, vol. 86(3), pages 449-484, June.
    47. Shishir Shakya & Collin Hodges, 2023. "Must‐access prescription drug monitoring programs and retail opioid sales," Contemporary Economic Policy, Western Economic Association International, vol. 41(1), pages 146-165, January.
    48. Jill Horwitz & Corey S. Davis & Lynn S. McClelland & Rebecca S. Fordon & Ellen Meara, 2018. "The Problem of Data Quality in Analyses of Opioid Regulation: The Case of Prescription Drug Monitoring Programs," NBER Working Papers 24947, National Bureau of Economic Research, Inc.
    49. Gearhart, Richard & Michieka, Nyakundi, 2021. "Provider availability, disease burdens, and opioid prescriptions," Economic Analysis and Policy, Elsevier, vol. 71(C), pages 371-383.
    50. David Powell & Rosalie Liccardo Pacula, 2020. "The Evolving Consequences of OxyContin Reformulation on Drug Overdoses," NBER Working Papers 26988, National Bureau of Economic Research, Inc.
    51. Kim, Bokyung, 2021. "Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences," Journal of Health Economics, Elsevier, vol. 75(C).
    52. Ruhm, Christopher J., 2019. "Drivers of the fatal drug epidemic," Journal of Health Economics, Elsevier, vol. 64(C), pages 25-42.
    53. William H. Dow & Anna Godøy & Christopher A. Lowenstein & Michael Reich, 2019. "Can Economic Policies Reduce Deaths of Despair?," NBER Working Papers 25787, National Bureau of Economic Research, Inc.
    54. Kasey Buckles & William N. Evans & Ethan M.J. Lieber, 2020. "The Drug Crisis and the Living Arrangements of Children," NBER Working Papers 27633, National Bureau of Economic Research, Inc.
    55. Powell, David & Pacula, Rosalie Liccardo & Taylor, Erin, 2020. "How increasing medical access to opioids contributes to the opioid epidemic: Evidence from Medicare Part D," Journal of Health Economics, Elsevier, vol. 71(C).
    56. Deiana, Claudio & Giua, Ludovica & Nistico, Roberto, 2019. "The Economics behind the Epidemic: Afghan Opium Price and Prescription Opioids in the US," IZA Discussion Papers 12872, Institute of Labor Economics (IZA).
    57. William N. Evans & Ethan Lieber & Patrick Power, 2018. "How the Reformulation of OxyContin Ignited the Heroin Epidemic," NBER Working Papers 24475, National Bureau of Economic Research, Inc.
    58. Yonatan Ben-Shalom & Megan McIntyre & Jia Pu & Marisa Shenk & Wenjia Zhu & William Shaw, "undated". "Workers’ Compensation and the Opioid Epidemic: State of the Field in Opioid Prescription Management," Mathematica Policy Research Reports 47a571e0762b43389e5f8e2b3, Mathematica Policy Research.
    59. Carolina Arteaga & Victoria Barone, 2023. "Democracy and The Opioid Epidemic," Working Papers tecipa-765, University of Toronto, Department of Economics.
    60. Birk, Erica G. & Waddell, Glen R., 2017. "The Mitigating Role of Prescription Drug Monitoring Programs in the Abuse of Prescription Drugs," IZA Discussion Papers 10990, Institute of Labor Economics (IZA).
    61. Laurence C. Baker & Kate Bundorf & Daniel Kessler, 2018. "The Effects of Medicare Advantage on Opioid Use," NBER Working Papers 25327, National Bureau of Economic Research, Inc.
    62. Böckerman, Petri & Kortelainen, Mika & Laine, Liisa & Nurminen, Mikko & Saxell, Tanja, 2019. "Digital Waste? Unintended Consequences of Health Information Technology," IZA Discussion Papers 12275, Institute of Labor Economics (IZA).
    63. Deiana Claudio & Giua Ludovica, 2021. "The Intended and Unintended Effects of Opioid Policies on Prescription Opioids and Crime," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 21(2), pages 751-792, April.
    64. Garin, Julio & Pohl, R. Vincent & Smith, Rhet A., 2018. "The Effect of Medical Cannabis Dispensaries on Opioid and Heroin Overdose Mortality," MPRA Paper 89613, University Library of Munich, Germany.
    65. Powell, David & Pacula, Rosalie Liccardo & Jacobson, Mireille, 2018. "Do medical marijuana laws reduce addictions and deaths related to pain killers?," Journal of Health Economics, Elsevier, vol. 58(C), pages 29-42.
    66. Gianmarco Daniele & Marco Le Moglie & Federico Masera, 2020. "Pains, Guns and Moves: The Effect of the US Opioid Epidemic on Mexican Migration," BAFFI CAREFIN Working Papers 20141, BAFFI CAREFIN, Centre for Applied Research on International Markets Banking Finance and Regulation, Universita' Bocconi, Milano, Italy.
    67. Geoffrey Joyce & Bo Zhou & Robert Kaestner, 2024. "Why higher copayments for opioids did not reduce use among Medicare beneficiaries," Health Economics, John Wiley & Sons, Ltd., vol. 33(3), pages 466-481, March.
    68. Thomas C. Buchmueller & Colleen M. Carey & Giacomo Meille, 2020. "How well do doctors know their patients? Evidence from a mandatory access prescription drug monitoring program," Health Economics, John Wiley & Sons, Ltd., vol. 29(9), pages 957-974, September.
    69. Simintzi, Elena & Ouimet, Paige & Ye, Kailei, 2019. "The Impact of the Opioid Crisis on Firm Value and Investment," CEPR Discussion Papers 14236, C.E.P.R. Discussion Papers.
    70. Abby Alpert & David Powell & Rosalie Liccardo Pacula, 2017. "Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids," NBER Working Papers 23031, National Bureau of Economic Research, Inc.
    71. Chen, Chong & Huang, Qianqian & Shi, Chang & Yuan, Tao, 2024. "Opioid epidemic and corporate innovation," Journal of Corporate Finance, Elsevier, vol. 86(C).
    72. Lucy Xiaolu Wang, 2021. "The complementarity of drug monitoring programs and health IT for reducing opioid‐related mortality and morbidity," Health Economics, John Wiley & Sons, Ltd., vol. 30(9), pages 2026-2046, September.
    73. Cecilia S. Diaz-Campo, M. Antonella Mancino, 2023. "What We RANDomly Did Not Learn: Opioid Elasticities and Underlying Mechanisms," LCERPA Working Papers bm0139, Laurier Centre for Economic Research and Policy Analysis.
    74. Alice M. Ellyson & Jevay Grooms & Alberto Ortega, 2022. "Flipping the script: The effects of opioid prescription monitoring on specialty‐specific provider behavior," Health Economics, John Wiley & Sons, Ltd., vol. 31(2), pages 297-341, February.
    75. Baker, Laurence C. & Bundorf, M. Kate & Kessler, Daniel P., 2020. "The effects of medicare advantage on opioid use," Journal of Health Economics, Elsevier, vol. 70(C).
    76. Ahomäki, Iiro & Pitkänen, Visa & Soppi, Aarni & Saastamoinen, Leena, 2020. "Impact of a physician-targeted letter on opioid prescribing," Journal of Health Economics, Elsevier, vol. 72(C).
    77. Deiana, Claudio & Giua, Ludovica, 2018. "The US Opidemic: Prescription Opioids, Labour Market Conditions and Crime," MPRA Paper 85712, University Library of Munich, Germany.
    78. Shishir Shakya & Jane E. Ruseski, 2023. "The effect of Prescription Drug Monitoring Programs on county‐level opioid prescribing practices and spillovers," Contemporary Economic Policy, Western Economic Association International, vol. 41(3), pages 435-454, July.
    79. Eichmeyer, Sarah & Zhang, Jonathan, 2023. "Primary care providers’ influence on opioid use and its adverse consequences," Journal of Public Economics, Elsevier, vol. 217(C).
    80. David Beheshti, 2019. "Adverse health effects of abuse‐deterrent opioids: Evidence from the reformulation of OxyContin," Health Economics, John Wiley & Sons, Ltd., vol. 28(12), pages 1449-1461, December.
    81. Robert Kaestner & Engy Ziedan, 2019. "Mortality and Socioeconomic Consequences of Prescription Opioids: Evidence from State Policies," NBER Working Papers 26135, National Bureau of Economic Research, Inc.
    82. Stith Sarah S., 2022. "Effects of work requirements for food assistance eligibility on disability claiming," IZA Journal of Labor Economics, Sciendo & Forschungsinstitut zur Zukunft der Arbeit GmbH (IZA), vol. 11(1), pages 1-31, January.
    83. Colleen Heflin & Xiaohan Sun, 2022. "Food Insecurity and the Opioid Crisis," The ANNALS of the American Academy of Political and Social Science, , vol. 703(1), pages 262-284, September.
    84. Sumedha Gupta & Morhaf Al Achkar & Bradley Ray, 2022. "Are prescription drug monitoring laws effective for all? Evidence from administrative data," Contemporary Economic Policy, Western Economic Association International, vol. 40(1), pages 28-47, January.
    85. Aparna Soni & Lindsey Bullinger & Christina Andrews & Amanda Abraham & Kosali Simon, 2024. "The impact of state Medicaid eligibility and benefits policy on neonatal abstinence syndrome hospitalizations," Contemporary Economic Policy, Western Economic Association International, vol. 42(1), pages 25-40, January.
    86. Johanna Catherine Maclean & Justine Mallatt & Christopher J. Ruhm & Kosali Simon, 2022. "The Opioid Crisis, Health, Healthcare, and Crime: A Review of Quasi-Experimental Economic Studies," The ANNALS of the American Academy of Political and Social Science, , vol. 703(1), pages 15-49, September.
    87. Andreyeva Elena & Ukert Benjamin, 2019. "The Impact of Medical Marijuana Laws and Dispensaries on Self-Reported Health," Forum for Health Economics & Policy, De Gruyter, vol. 22(2), pages 1-20, December.
    88. Resul Cesur & Joseph J. Sabia & W. David Bradford, 2019. "Did the War on Terror Ignite an Opioid Epidemic?," NBER Working Papers 26264, National Bureau of Economic Research, Inc.
    89. Casey B. Mulligan, 2020. "Prices and Federal Policies in Opioid Markets," Working Papers 2020-10, Becker Friedman Institute for Research In Economics.
    90. Lowenstein, Christopher, 2024. "“Deaths of despair” over the business cycle: New estimates from a shift-share instrumental variables approach," Economics & Human Biology, Elsevier, vol. 53(C).
    91. McMichael, Benjamin J. & Van Horn, R. Lawrence & Viscusi, W. Kip, 2020. "The impact of cannabis access laws on opioid prescribing," Journal of Health Economics, Elsevier, vol. 69(C).
    92. Dillender, Marcus, 2018. "What happens when the insurer can say no? Assessing prior authorization as a tool to prevent high-risk prescriptions and to lower costs," Journal of Public Economics, Elsevier, vol. 165(C), pages 170-200.
    93. Casey B. Mulligan, 2020. "Prices and Federal Policies in Opioid Markets," NBER Working Papers 26812, National Bureau of Economic Research, Inc.
    94. Resul Cesur & Joseph J. Sabia & W. David Bradford, 2024. "The effect of combat deployments on veteran opioid abuse," Health Economics, John Wiley & Sons, Ltd., vol. 33(6), pages 1284-1318, June.
    95. Doleac, Jennifer & Mukherjee, Anita, 2018. "The Moral Hazard of Lifesaving Innovations: Naloxone Access, Opioid Abuse, and Crime," IZA Discussion Papers 11489, Institute of Labor Economics (IZA).
    96. Cornelius A. Rietveld & Pankaj C. Patel, 2021. "Prescription opioids and new business establishments," Small Business Economics, Springer, vol. 57(3), pages 1175-1199, October.
    97. Gal Wettstein, 2019. "Health insurance and opioid deaths: Evidence from the Affordable Care Act young adult provision," Health Economics, John Wiley & Sons, Ltd., vol. 28(5), pages 666-677, May.
    98. Dow, William H. & Godøy, Anna & Lowenstein, Christopher & Reich, Michael, 2020. "Can Labor Market Policies Reduce Deaths of Despair?," Journal of Health Economics, Elsevier, vol. 74(C).
    99. Thomas Lebesmuehlbacher & Rhet A. Smith, 2021. "The effect of medical cannabis laws on pharmaceutical marketing to physicians," Health Economics, John Wiley & Sons, Ltd., vol. 30(10), pages 2409-2436, September.

Articles

  1. Thomas C. Buchmueller & Colleen Carey, 2018. "The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare," American Economic Journal: Economic Policy, American Economic Association, vol. 10(1), pages 77-112, February.
    See citations under working paper version above.
  2. Colleen Carey, 2017. "Technological Change and Risk Adjustment: Benefit Design Incentives in Medicare Part D," American Economic Journal: Economic Policy, American Economic Association, vol. 9(1), pages 38-73, February.

    Cited by:

    1. Bijlsma, Michiel & Boone, Jan & Zwart, Gijsbert, 2017. "The complementarity between risk adjustment and community rating: Distorting market outcomes to facilitate redistribution," Journal of Public Economics, Elsevier, vol. 155(C), pages 21-37.
    2. Pilny, Adam & Wübker, Ansgar & Ziebarth, Nicolas R., 2017. "Introducing Risk Adjustment and Free Health Plan Choice in Employer-Based Health Insurance: Evidence from Germany," VfS Annual Conference 2017 (Vienna): Alternative Structures for Money and Banking 168121, Verein für Socialpolitik / German Economic Association.
    3. Peter Paul Klein & Richard van Kleef & Josefa Henriquez & Francesco Paolucci, 2023. "The interplay between risk adjustment and risk rating in voluntary health insurance," Journal of Risk & Insurance, The American Risk and Insurance Association, vol. 90(1), pages 59-91, March.
    4. Michele Fioretti & Hongming Wang, 2019. "Subsidizing Inequality: Performance Pay and Risk Selection in Medicare," SciencePo Working papers hal-03393070, HAL.
    5. A. A. Withagen-Koster & R. C. Kleef & F. Eijkenaar, 2020. "Incorporating self-reported health measures in risk equalization through constrained regression," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 513-528, June.
    6. Amanda Starc & Robert J. Town, 2015. "Externalities and Benefit Design in Health Insurance," NBER Working Papers 21783, National Bureau of Economic Research, Inc.
    7. Carey, Colleen, 2021. "Sharing the burden of subsidization: Evidence on pass-through from a subsidy revision in Medicare Part D," Journal of Public Economics, Elsevier, vol. 198(C).
    8. Maria Polyakova, 2015. "Regulation of Insurance with Adverse Selection and Switching Costs: Evidence from Medicare Part D," NBER Working Papers 21541, National Bureau of Economic Research, Inc.
    9. Decarolis, Francesco & Guglielmo, Andrea, 2017. "Insurers’ response to selection risk: Evidence from Medicare enrollment reforms," Journal of Health Economics, Elsevier, vol. 56(C), pages 383-396.
    10. Richard C. van Kleef & René C. J. A. van Vliet, 2022. "How to deal with persistently low/high spenders in health plan payment systems?," Health Economics, John Wiley & Sons, Ltd., vol. 31(5), pages 784-805, May.
    11. Michele Fioretti & Hongming Wang, 2021. "Performance Pay in Insurance Markets: Evidence from Medicare," Post-Print hal-03791843, HAL.
    12. David Dranove & Christopher Ody & Amanda Starc, 2017. "A Dose of Managed Care: Controlling Drug Spending in Medicaid," NBER Working Papers 23956, National Bureau of Economic Research, Inc.
    13. Michael Geruso & Timothy J. Layton & Grace McCormack & Mark Shepard, 2023. "The Two-Margin Problem in Insurance Markets," The Review of Economics and Statistics, MIT Press, vol. 105(2), pages 237-257, March.
    14. Timothy J. Layton & Thomas G. McGuire & Richard C. van Kleef, 2016. "Deriving Risk Adjustment Payment Weights to Maximize Efficiency of Health Insurance Markets," NBER Working Papers 22642, National Bureau of Economic Research, Inc.
    15. Daniel P. Miller & Jungwon Yeo, 2019. "The Consequences of a Public Health Insurance Option: Evidence from Medicare Part D," American Journal of Health Economics, MIT Press, vol. 5(2), pages 191-226, Spring.
    16. Jeffrey Clemens & Jonathan M. Leganza & Alex Masucci, 2023. "Plugging Gaps in Payment Systems: Evidence from the Take-Up of New Medicare Billing Codes," NBER Working Papers 31336, National Bureau of Economic Research, Inc.
    17. Mark Shepard, 2016. "Hospital Network Competition and Adverse Selection: Evidence from the Massachusetts Health Insurance Exchange," NBER Working Papers 22600, National Bureau of Economic Research, Inc.
    18. Aparna Soni, 2024. "Estimating price elasticities of demand for pain relief drugs: evidence from Medicare Part D," International Journal of Health Economics and Management, Springer, vol. 24(4), pages 481-515, December.
    19. Michael Geruso & Timothy Layton, 2017. "Selection in Health Insurance Markets and Its Policy Remedies," NBER Working Papers 23876, National Bureau of Economic Research, Inc.
    20. Keith Marzilli Ericson & Kimberley Geissler & Benjamin Lubin, 2017. "The Impact of Partial-Year Enrollment on the Accuracy of Risk Adjustment Systems: A Framework and Evidence," NBER Working Papers 23765, National Bureau of Economic Research, Inc.
    21. Withagen-Koster, Anja A. & van Kleef, Richard C. & Eijkenaar, Frank, 2023. "Predictable profits and losses in a health insurance market with risk equalization: A multiple-contract period perspective," Health Policy, Elsevier, vol. 131(C).
    22. Bergquist, Savannah L. & Layton, Timothy J. & McGuire, Thomas G. & Rose, Sherri, 2019. "Data transformations to improve the performance of health plan payment methods," Journal of Health Economics, Elsevier, vol. 66(C), pages 195-207.
    23. Michael Geruso & Timothy Layton & Daniel Prinz, 2019. "Screening in Contract Design: Evidence from the ACA Health Insurance Exchanges," American Economic Journal: Economic Policy, American Economic Association, vol. 11(2), pages 64-107, May.
    24. Kurt Lavetti & Kosali Simon, 2016. "Strategic Formulary Design in Medicare Part D Plans," NBER Working Papers 22338, National Bureau of Economic Research, Inc.
    25. Martin Andersen, 2017. "Constraints on Formulary Design Under the Affordable Care Act," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 160-178, December.
    26. Savannah L. Bergquist & Timothy J. Layton & Thomas G. McGuire & Sherri Rose, 2018. "Intervening on the Data to Improve the Performance of Health Plan Payment Methods," NBER Working Papers 24491, National Bureau of Economic Research, Inc.
    27. Amanda R. Kreider & Timothy J. Layton & Mark Shepard & Jacob Wallace, 2022. "Adverse Selection and Network Design Under Regulated Plan Prices: Evidence from Medicaid," NBER Working Papers 30719, National Bureau of Economic Research, Inc.
    28. Jonathan Gruber, 2017. "Delivering Public Health Insurance through Private Plan Choice in the United States," Journal of Economic Perspectives, American Economic Association, vol. 31(4), pages 3-22, Fall.
    29. Francesco Decarolis & Andrea Guglielmo & Calvin Luscombe, 2017. "Open Enrollment Periods and Plan Choices," NBER Working Papers 24156, National Bureau of Economic Research, Inc.
    30. Daniel W. Sacks & Khoa Vu & Tsan‐Yao Huang & Pinar Karaca‐Mandic, 2021. "How do insurance firms respond to financial risk sharing regulations? Evidence from the Affordable Care Act," Health Economics, John Wiley & Sons, Ltd., vol. 30(6), pages 1443-1460, June.
    31. Lieber, Ethan M.J., 2018. "Does health insurance coverage fall when nonprofit insurers become for-profits?," Journal of Health Economics, Elsevier, vol. 57(C), pages 75-88.
    32. Benjamin R. Handel & Jonathan T. Kolstad, 2021. "The Affordable Care Act After a Decade: Industrial Organization of the Insurance Exchanges," NBER Working Papers 29178, National Bureau of Economic Research, Inc.
    33. Anna Zink & Sherri Rose, 2020. "Fair regression for health care spending," Biometrics, The International Biometric Society, vol. 76(3), pages 973-982, September.
    34. Dillender, Marcus, 2018. "What happens when the insurer can say no? Assessing prior authorization as a tool to prevent high-risk prescriptions and to lower costs," Journal of Public Economics, Elsevier, vol. 165(C), pages 170-200.
    35. Tomas Pedro Sanguinetti, 2019. "How Do Couples Choose Individual Insurance Plans? Evidence from Medicare Part D," 2019 Papers psa1760, Job Market Papers.

  3. Colleen Carey & Stephen H. Shore, 2013. "From the Peaks to the Valleys: Cross-State Evidence on Income Volatility over the Business Cycle," The Review of Economics and Statistics, MIT Press, vol. 95(2), pages 549-562, May.

    Cited by:

    1. Andrew C. Chang & Phillip Li, 2015. "Is Economics Research Replicable? Sixty Published Papers from Thirteen Journals Say \"Usually Not\"," Finance and Economics Discussion Series 2015-83, Board of Governors of the Federal Reserve System (U.S.).
    2. Silvia Avram & Mike Brewer & Paul Fisher & Laura Fumagalli, 2022. "Household Earnings and Income Volatility in the UK, 2009–2017," The Journal of Economic Inequality, Springer;Society for the Study of Economic Inequality, vol. 20(2), pages 345-369, June.
    3. Deng, Liuchun & Krishna, Pravin & Senses, Mine Zeynep & Stegmaier, Jens, 2021. "Trade, Human Capital, and Income Risk," IZA Discussion Papers 14953, Institute of Labor Economics (IZA).
    4. Andrew C. Chang & Phillip Li, 2018. "Measurement Error In Macroeconomic Data And Economics Research: Data Revisions, Gross Domestic Product, And Gross Domestic Income," Economic Inquiry, Western Economic Association International, vol. 56(3), pages 1846-1869, July.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 1 paper announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-HEA: Health Economics (1) 2017-02-26

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Colleen Marie Carey should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.